Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia

Am J Hematol. 2019 Jul;94(7):E196-E198. doi: 10.1002/ajh.25496. Epub 2019 May 3.

Authors

Marie Hogan¹, Julia T Geyer², James B Bussel³

Affiliations

¹ Division of Pediatric Hematology/Oncology, Department of Pediatrics, New York University, New York, New York.
² Division of Hematopathology, New York-Presbyterian/Weill Cornell Medical College, New York, New York.
³ Division of Pediatric Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, New York.

PMID: 31012979
DOI: 10.1002/ajh.25496

No abstract available

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Bone Marrow* / metabolism
Bone Marrow* / pathology
Child
Child, Preschool
Female
Humans
Male
Megakaryocytes* / metabolism
Megakaryocytes* / pathology
Purpura, Thrombocytopenic, Idiopathic* / drug therapy
Purpura, Thrombocytopenic, Idiopathic* / metabolism
Purpura, Thrombocytopenic, Idiopathic* / pathology
Thrombopoiesis / drug effects*